[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"stock-detail-IMNN":3,"homepage-market-summary":30,"stock-news-IMNN":174},{"ticker":4,"date":5,"profile":6,"dividend":9,"quote":15},"IMNN","2026-10-05",{"name":7,"exchange":8,"sector":9,"industry":10,"description":11,"ceo":9,"employees":12,"headquarters":13,"founded":9,"is_fund":14,"issuer":9,"category":9},"Imunon, Inc. Common Stock","Nasdaq",null,"PHARMACEUTICAL PREPARATIONS","Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit an immunological response. The company's clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer.","20","Lawrenceville, NJ",false,{"close":16,"open":17,"high":18,"low":19,"prev_close":20,"change":21,"percent_change":22,"volume":23,"transactions":24,"vwap":25,"high_52w":26,"low_52w":19,"avg_volume_52w":27,"range_52w_percent":28,"record_count":29},1.24,1.3,1.32,1.22,1.28,-0.04,-3.12,82576.887389,579,1.2599,5.4,91359.21944958964,0.5,6942,{"status":31,"indices":32,"watchlist":77,"sectors":99,"benchmarks":153},"success",[33,42,49,56,63,70],{"symbol":34,"name":35,"price":36,"change":37,"pct_change":38,"is_up":39,"sparkline":40,"date":41},"SPX","S&P 500",7722.72,56.27,0.73,true,"0.0,5.0 2.3,8.0 4.6,10.4 6.9,13.4 9.3,9.1 11.6,11.5 13.9,13.8 16.2,16.0 18.5,10.3 20.8,9.5 23.2,2.0 25.5,2.0 27.8,5.9 30.1,6.0 32.4,3.4 34.7,7.3 37.1,8.2 39.4,9.4 41.7,8.5 44.0,4.8","2026-10-02",{"symbol":43,"name":44,"price":45,"change":46,"pct_change":47,"is_up":39,"sparkline":48,"date":41},"NDX","NASDAQ 100",30807.93,306.37,1,"0.0,11.5 2.3,11.7 4.6,12.4 6.9,14.8 9.3,12.8 11.6,14.6 13.9,16.0 16.2,15.9 18.5,12.2 20.8,10.7 23.2,4.4 25.5,2.6 27.8,4.5 30.1,4.5 32.4,3.5 34.7,6.0 37.1,5.5 39.4,5.0 41.7,4.3 44.0,2.0",{"symbol":50,"name":51,"price":52,"change":53,"pct_change":54,"is_up":39,"sparkline":55,"date":41},"DJI","DOW JONES",51177,250,0.49,"0.0,2.0 2.3,5.5 4.6,7.8 6.9,9.5 9.3,6.7 11.6,7.5 13.9,9.4 16.2,12.9 18.5,11.1 20.8,11.7 23.2,9.6 25.5,10.7 27.8,12.6 30.1,13.5 32.4,10.8 34.7,12.8 37.1,13.5 39.4,16.0 41.7,15.9 44.0,14.5",{"symbol":57,"name":58,"price":59,"change":60,"pct_change":61,"is_up":39,"sparkline":62,"date":41},"COMP","NASDAQ Composite",27190.86,319.27,1.19,"0.0,10.2 2.3,11.1 4.6,13.0 6.9,14.9 9.3,12.1 11.6,13.7 13.9,16.0 16.2,16.0 18.5,11.1 20.8,10.0 23.2,3.4 25.5,2.0 27.8,5.4 30.1,5.4 32.4,3.9 34.7,6.7 37.1,6.9 39.4,6.2 41.7,6.1 44.0,2.6",{"symbol":64,"name":65,"price":66,"change":67,"pct_change":68,"is_up":39,"sparkline":69,"date":41},"RUT","RUSSELL 2000",2815.2,25,0.9,"0.0,2.0 2.3,3.0 4.6,6.1 6.9,8.4 9.3,7.5 11.6,8.8 13.9,10.4 16.2,11.3 18.5,10.2 20.8,11.2 23.2,10.1 25.5,8.8 27.8,12.9 30.1,13.1 32.4,12.8 34.7,14.4 37.1,15.1 39.4,16.0 41.7,15.1 44.0,13.2",{"symbol":71,"name":72,"price":73,"change":74,"pct_change":75,"is_up":14,"sparkline":76,"date":41},"VIX","CBOE VIX",15.31,-1.08,-6.59,"0.0,14.8 2.3,10.2 4.6,7.3 6.9,2.0 9.3,9.7 11.6,4.9 13.9,4.5 16.2,2.5 18.5,11.3 20.8,13.7 23.2,13.5 25.5,16.0 27.8,12.3 30.1,10.4 32.4,13.5 34.7,8.8 37.1,8.9 39.4,7.8 41.7,7.6 44.0,11.8",[78,85,92],{"symbol":79,"name":80,"price":81,"change":82,"pct_change":83,"is_up":39,"sparkline":84,"date":5},"NVDA","NVIDIA Corp",238.9,4.95,2.12,"0.0,16.0 7.3,12.2 14.7,13.8 22.0,12.6 29.3,10.1 36.7,7.0 44.0,2.0",{"symbol":86,"name":87,"price":88,"change":89,"pct_change":90,"is_up":14,"sparkline":91,"date":5},"AAPL","Apple Inc",332.89,-0.8,-0.24,"0.0,2.0 7.3,5.2 14.7,16.0 22.0,11.7 29.3,14.9 36.7,10.9 44.0,11.8",{"symbol":93,"name":94,"price":95,"change":96,"pct_change":97,"is_up":39,"sparkline":98,"date":5},"TSLA","Tesla Inc",378.69,8.1,2.18,"0.0,5.6 7.3,13.5 14.7,16.0 22.0,14.9 29.3,15.3 36.7,6.4 44.0,2.0",[100,105,109,114,119,124,129,134,139,144,148],{"name":101,"etf":102,"change":103,"price":104,"is_up":39},"Technology","XLK",0.56,200.93,{"name":106,"etf":107,"change":38,"price":108,"is_up":39},"Financials","XLF",53.88,{"name":110,"etf":111,"change":112,"price":113,"is_up":39},"Healthcare","XLV",0.72,167.37,{"name":115,"etf":116,"change":117,"price":118,"is_up":39},"Consumer Cycl","XLY",0.35,110.42,{"name":120,"etf":121,"change":122,"price":123,"is_up":39},"Consumer Staples","XLP",0.63,81.04,{"name":125,"etf":126,"change":127,"price":128,"is_up":39},"Energy","XLE",0.99,63.44,{"name":130,"etf":131,"change":132,"price":133,"is_up":39},"Industrials","XLI",0.09,170.1,{"name":135,"etf":136,"change":137,"price":138,"is_up":39},"Materials","XLB",1.31,49.5,{"name":140,"etf":141,"change":142,"price":143,"is_up":14},"Real Estate","XLRE",-0.34,40.67,{"name":145,"etf":146,"change":117,"price":147,"is_up":39},"Utilities","XLU",39.97,{"name":149,"etf":150,"change":151,"price":152,"is_up":39},"Comm Services","XLC",1.17,111.61,[154,159,164,169],{"ticker":155,"name":156,"price":157,"change":158,"is_up":39},"SPY","SPDR S&P 500 ETF",774.83,0.67,{"ticker":160,"name":161,"price":162,"change":163,"is_up":39},"QQQ","Invesco QQQ Trust",756.2,0.88,{"ticker":165,"name":166,"price":167,"change":168,"is_up":39},"DIA","SPDR Dow Jones ETF",512.11,0.2,{"ticker":170,"name":171,"price":172,"change":173,"is_up":39},"IWM","iShares Russell 2000",283.39,0.66,{"ticker":4,"count":175,"articles":176},12,[177,183,189,195,200,206,211,217,222,227,232,237],{"title":178,"link":179,"pubDate":180,"description":181,"source":182},"IDMC Recommends Continuation of Phase 2 MRD Study of IMNN-001 in Advanced Ovarian Cancer - onclive.com","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMiuAFBVV95cUxNTUtfQjhiYVA5N3Y1bUdkSnhMYjc4VmlvMzkwaDUxYWxUd0g2ZUtLM3RrWXRiX2VuMjRuLVJsckpCNnB5QUNCTzcyRXZ3UGpYMVA2bF9DMm1UY2dBWDg4U1ZvRU5yTDNYOVdIdUlzcEE1YVI3Q2ltekJpcVpNWVIwbWdYNml3d0xzZDhnanJSTF9KRUxPQzJxMmJwWTBkVFBHQW84LXRxSUtqcDVLQjY2VHBHSTdtNWJp?oc=5","Wed, 23 Sep 2026 07:00:00 GMT","IDMC Recommends Continuation of Phase 2 MRD Study of IMNN-001 in Advanced Ovarian Cancer onclive.com","onclive.com",{"title":184,"link":185,"pubDate":186,"description":187,"source":188},"A debt swap cuts IMUNON’s outstanding debt by about 43%, with no common shares issued. - Stock Titan","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMimAFBVV95cUxPb2hpQ3JnQXVpVWRLTkhEV25OdThGcThSN2x6MlFlaVR6MUFXTTlwd0NHd3gtM1JJclprbFl1QVMwOTV2eURMMlEydHdKY1JEanpHNWNqcTNkM2FJM0pyWGkxWDZBbzM3N1lGUk9Bcks3NkpJcXQyUWhvZEdlcVdVYUN0a015a2FDUG5pdXhOUVNvZFhlRnVCYQ?oc=5","Tue, 29 Sep 2026 12:00:00 GMT","A debt swap cuts IMUNON’s outstanding debt by about 43%, with no common shares issued. Stock Titan","Stock Titan",{"title":190,"link":191,"pubDate":192,"description":193,"source":194},"Imunon, Inc. (IMNN) Shareholder\u002FAnalyst Call - Slideshow (NASDAQ:IMNN) 2026-09-24 - Seeking Alpha","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMilgFBVV95cUxObDk1RTYwYnpHa0dtblZ1dlR4eFJsRWdkaUQ2SU9OUm43c0VoNmV2dGhRcllWNGVXOUFfQUdOUXhFTHAxLXNGanFhVEpkX1VWS1kyTnBfRkhfOWpBUW5nYXBCNzNHdkV1QVFBd1hDWDFaTW04cDhZM3hULTRycU9tUWczb2xRTUZ3TEt6SjV3aHVsTUx4ZXc?oc=5","Thu, 24 Sep 2026 07:00:00 GMT","Imunon, Inc. (IMNN) Shareholder\u002FAnalyst Call - Slideshow (NASDAQ:IMNN) 2026-09-24 Seeking Alpha","Seeking Alpha",{"title":196,"link":197,"pubDate":198,"description":199,"source":188},"No serious immune-related side effects seen so far in ovarian cancer study - Stock Titan","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMiugFBVV95cUxNWE81TU1JUmd6a0tjcnFfOFlieUN5dkdCMmJ3dk9Ca3JRUHI4eW16UlNzWnhPa2NjcXJDNTlZMjBKWW9wTjhXcVhuS3Jza0p4WEV1bFZwRFd4a2JBSFJwM3JYbFRmamJSWG5lZmtISV9IWTNCWGptZjJSUU5JeFdEbzhrRU9pWE45YTNtOUktWVdiYVZlRFVHRmhCVmhJUzczVlFuaFFqZGFvejVkSGZVcUFNY3VORktULVE?oc=5","Tue, 22 Sep 2026 07:00:00 GMT","No serious immune-related side effects seen so far in ovarian cancer study Stock Titan",{"title":201,"link":202,"pubDate":203,"description":204,"source":205},"Imunon Inc. (IMNN) Shares Edge Higher to $1.43 as Stock Presses Against $1.50 Resistance - Low Vol Factor - siam.in","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMiwgFBVV95cUxNb05HVmx4VGxnN1VodjdUTFhkR3BVakRoUWdFMWNEeTRIcVE4STBYMDc1eHdpR0ZwLWVLOHdtZTJ5dVlxNHdkaWRpLTRzZ1BwQ3dnYnJQTkRTT2o4S0FJblgzZkZrQldmenlWakd6eFE2ZklyeUtvTVJUNnRER1hjdi0zWmdmY3Jsa0hNU1E4dHhNeEd3NmVud3JxeGhWWTJkaTBsRUpNUDQxQlhUTFZUdWI4RXZkWUNjOWw0ZElqMWNVdw?oc=5","Mon, 28 Sep 2026 17:48:24 GMT","Imunon Inc. (IMNN) Shares Edge Higher to $1.43 as Stock Presses Against $1.50 Resistance - Low Vol Factor siam.in","siam.in",{"title":207,"link":208,"pubDate":186,"description":209,"source":210},"IMUNON Converts $1.2 Million of Debt-to-Equity - GlobeNewswire","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMiuAFBVV95cUxQb0RpRlFaQlJldFp3LWdySjlPWXBMWXhqT2tXWUpIZ3J0aVQtVnN3MFgwQUJwamQzY3pFdVdRZGE2S0hMLXZqMjdQSk9NY05LY2JwaGw0REJ1QmRZYUFoZ2lqVDdDS1UwM2JJY2tDcXpXUXZIYXcxbTJWcjYzamc3ZUZ1REp2WjBrZmptakd5akJUcV9jSEJJN2VZTWg0eU1fWkRkR1VuYTFXVTRKVWJWaG9ZOWhla05X?oc=5","IMUNON Converts $1.2 Million of Debt-to-Equity GlobeNewswire","GlobeNewswire",{"title":212,"link":213,"pubDate":214,"description":215,"source":216},"IMNN 8-K & SEC Filings - finance.yahoo.com","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMieEFVX3lxTE5JNF92QllhbmoxdTJDZEJRSHFGeGRLcnRENzdaMVhrZWFkb1FYX2VFMGt6TjlZZUxuQUtOYWdHUTd1MkZ4aExhZ0hTbUtaZ0ZxSmxHdkcwY1JhdGZzTVdnMWN5Ry0zUXQyMDREVEdEUkNsYlcxbGYtQw?oc=5","Tue, 29 Sep 2026 07:00:00 GMT","IMNN 8-K & SEC Filings finance.yahoo.com","finance.yahoo.com",{"title":218,"link":219,"pubDate":220,"description":221,"source":188},"A 7,169-share salary award leaves Imunon (IMNN) chair with 103,921 shares held directly. - Stock Titan","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMipwFBVV95cUxQUEhkTktXRTl2b3JoSlFVMXNnYjg2QTdqcVJKTm1RZFh2ZUhYenFoR0pUaWlTZkthbER4TThac0dvWThURVJNLWVLXzR6SzNjTmg0Ym0wR2Y4N2xBWTUyOFc3UHo5bWl5eGdQdnBDZmQ3RDZTanRUbWZCVF81UUZLRUtqLVdvN0dRazh6SENRRzBUcjBBejRzbGJsajVwNHRtWW5GbDdRMA?oc=5","Mon, 28 Sep 2026 20:32:28 GMT","A 7,169-share salary award leaves Imunon (IMNN) chair with 103,921 shares held directly. Stock Titan",{"title":223,"link":224,"pubDate":225,"description":226,"source":188},"At $1.41 a share, Imunon (IMNN) granted its medical chief 4,390 shares in place of part of his cash salary. - Stock Titan","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMipwFBVV95cUxOMmw1RzQwaTYzOEgzak5kTkt5cnd2UEMyX3Z0bm5vRjNNVTVQakI2bEpaYmVtbVN5bzVKZ09iM0lVcXVOVkJ4Q290cGZSX05UMUdkMHZLam9aTjZCdUI0VjVGbzRYbTF5T1hveVpoeW5nd3R1STNvVE03Yms4RGR3YWhkNDIwZm9DRndxeXlCa2JjR2pQLTN6b0tSUjJXUDVyYVFOSVdENA?oc=5","Mon, 28 Sep 2026 20:30:10 GMT","At $1.41 a share, Imunon (IMNN) granted its medical chief 4,390 shares in place of part of his cash salary. Stock Titan",{"title":228,"link":229,"pubDate":230,"description":231,"source":188},"Part of the CEO’s salary came as stock: Imunon (IMNN) granted Stacy Lindborg 6,697 shares. - Stock Titan","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMipwFBVV95cUxPRWFmZlJrTmtDRWRJTUkwQndlUnhsY2hwWmVTQkRzZk1MdTZ6UmFEbktMQm1RLVgxR0hBOXhsNzE1OXpXTnJ4dmstbjF3NEZrR0RLQW9tVnBOTmJFSXRVQzZMYW93NTNnbzVVOGNsa1Y0TWxYOUNQNl9ubk1XYTBrX29lbWh0b3BxYkpkSUh1NkV2anJ4TC1lZmJKOHBGTk82OGdTMVJtMA?oc=5","Mon, 28 Sep 2026 20:31:12 GMT","Part of the CEO’s salary came as stock: Imunon (IMNN) granted Stacy Lindborg 6,697 shares. Stock Titan",{"title":233,"link":234,"pubDate":235,"description":236,"source":188},"A patient in an ovarian cancer trial reports no recurrence nearly 10 years after diagnosis - Stock Titan","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMiugFBVV95cUxQeHoyNllDSmtIOElpZHU0bXM2Sjg0MkptWGZVdGsyZWJPSWxoSkdlTG5zUExHOU1jNThiOU1sRFkyMUpkR2ZnUHd0Z2N6QUk4bm9kSGhZNk9RWjA2QUtlQVVhQy03TzU3MGU1LUFEMDJyNThPQmw0QWVJdXJ1UVpkdDBNMjBtU0dRNE5wdW1aYlIySDU2aG5aaXNJVXFDREhUY01TV3hrdUIzcV90aG00enFXWlFpT2loZ3c?oc=5","Thu, 24 Sep 2026 12:05:00 GMT","A patient in an ovarian cancer trial reports no recurrence nearly 10 years after diagnosis Stock Titan",{"title":238,"link":239,"pubDate":240,"description":241,"source":242},"Imunon Introduces Series B Preferred to Restructure Debt - TipRanks","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMirAFBVV95cUxNaXVUcU9KSW9yTTl4MnN5YWtWRFBuVEZHRDNra3R6djU2TGpoVWNkMXNZa1RnMVRGdW1HUGRySkZoSzY3RlB5cVlHSkE4Y1V2X0RYYlFWcDJVcmF6a2hqaWloVng3aFhhZTNYRGZFUnlPRFRQUU1VdTQ5Z3p5WWxldDk2UU5ETThLczBiWll1MXE4SW5EYjRpQjBvZnBUSmRFbHZKQlJkWnFQZU9x?oc=5","Tue, 29 Sep 2026 12:38:54 GMT","Imunon Introduces Series B Preferred to Restructure Debt TipRanks","TipRanks"]